Antibodies to fibroblast growth factor (FGF23)

• US 7,314,618 B2
• Filed: 03/04/2003
• Issued: 01/01/2008
• Est. Priority Date: 07/19/2000
• Status: Expired due to Term

• Current Assignee: ADVANCED RESEARCH & TECHNOLOGY INSTITUTE, Ludwig-Maximilians-Universtat Munchen
• Original Assignee: ADVANCED RESEARCH & TECHNOLOGY INSTITUTE, Ludwig-Maximilians-Universtat Munchen
• Inventors: Meitinger, Thomas, Strom, Tim Matthias, White, Ken, Econs, Michael
• Primary Examiner(s): Saoud; Christine J.
• Application Number:
  US10/379,334
• Publication Number:
  US 20030181379A1
• Time in Patent Office: 1,764 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 3/12 for electrolyte homeostasis
• CPC Class Codes: C07K 14/50 Fibroblast growth factor [FGF]
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The present invention relates to antibodies that bind to FGF23 polypeptides and to FGF23 mutant polypeptides.

Claims

1. An antibody that specifically binds with a fibroblast growth factor-23 FGF(23) polypeptide as set forth in SEQ ID NO:

2.

2. The antibody of claim 1, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a humanized antibody, a chimeric antibody, and a synthetic antibody.

3. A composition comprising the antibody of claim 1 and a pharmaceutically-acceptable carrier.

4. An antibody that specifically binds with a mutant FGF23 polypeptide, wherein said mutant FGF23 polypeptide is a mutant of SEQ ID NO:

2, wherein said mutant FGF23 polypeptide consists of at least one mutation selected from the group consisting of a mutation to amino acid residue 176 of SEQ ID NO;

2 and a mutation to amino acid residue 179 of SEQ ID NO;

2.